• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Diabetologia Phenotypic Characteristics and Prognosis of Inpatients With COVID-19 and Diabetes: The CORONADO Study

tetano

Editor, Senior Moderator
Diabetologia


. 2020 May 29.
doi: 10.1007/s00125-020-05180-x. Online ahead of print.
Phenotypic Characteristics and Prognosis of Inpatients With COVID-19 and Diabetes: The CORONADO Study


Bertrand Cariou[SUP] 1 [/SUP], Samy Hadjadj[SUP] 2 [/SUP], Matthieu Wargny[SUP] 3 4 [/SUP], Matthieu Pichelin[SUP] 3 [/SUP], Abdallah Al-Salameh[SUP] 5 [/SUP], Ingrid Allix[SUP] 6 [/SUP], Coralie Amadou[SUP] 7 [/SUP], Gw?na?lle Arnault[SUP] 8 [/SUP], Florence Baudoux[SUP] 9 [/SUP], Bernard Bauduceau[SUP] 10 11 [/SUP], Sophie Borot[SUP] 12 [/SUP], Muriel Bourgeon-Ghittori[SUP] 13 [/SUP], Olivier Bourron[SUP] 14 [/SUP], David Boutoille[SUP] 15 [/SUP], France Cazenave-Roblot[SUP] 16 17 [/SUP], Claude Chaumeil[SUP] 18 [/SUP], Emmanuel Cosson[SUP] 19 20 [/SUP], Sandrine Coudol[SUP] 4 [/SUP], Patrice Darmon[SUP] 21 [/SUP], Emmanuel Disse[SUP] 22 [/SUP], Am?lie Ducet-Boiffard[SUP] 23 [/SUP], B?n?dicte Gaborit[SUP] 24 [/SUP], Michael Joubert[SUP] 25 [/SUP], V?ronique Kerlan[SUP] 26 [/SUP], Bruno Laviolle[SUP] 27 [/SUP], Lucien Marchand[SUP] 28 [/SUP], Laurent Meyer[SUP] 29 [/SUP], Louis Potier[SUP] 30 [/SUP], Ga?tan Prevost[SUP] 31 [/SUP], Jean-Pierre Riveline[SUP] 32 33 34 [/SUP], Ren? Robert[SUP] 35 [/SUP], Pierre-Jean Saulnier[SUP] 36 [/SUP], Ariane Sultan[SUP] 37 [/SUP], Jean-Fran?ois Th?baut[SUP] 18 [/SUP], Charles Thivolet[SUP] 38 39 [/SUP], Blandine Tramunt[SUP] 40 [/SUP], Camille Vatier[SUP] 41 42 [/SUP], Ronan Roussel[SUP] 30 [/SUP], Jean-Fran?ois Gautier[SUP] 32 34 [/SUP], Pierre Gourdy[SUP] 40 [/SUP], CORONADO investigators



Affiliations

Abstract

Aims/hypothesis: Coronavirus disease-2019 (COVID-19) is a life-threatening infection caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus. Diabetes has rapidly emerged as a major comorbidity for COVID-19 severity. However, the phenotypic characteristics of diabetes in COVID-19 patients are unknown.
Methods: We conducted a nationwide multicentre observational study in people with diabetes hospitalised for COVID-19 in 53 French centres in the period 10-31 March 2020. The primary outcome combined tracheal intubation for mechanical ventilation and/or death within 7 days of admission. Age- and sex-adjusted multivariable logistic regressions were performed to assess the prognostic value of clinical and biological features with the endpoint. ORs are reported for a 1 SD increase after standardisation.
Results: The current analysis focused on 1317 participants: 64.9% men, mean age 69.8 ? 13.0 years, median BMI 28.4 (25th-75th percentile: 25.0-32.7) kg/m[SUP]2[/SUP]; with a predominance of type 2 diabetes (88.5%). Microvascular and macrovascular diabetic complications were found in 46.8% and 40.8% of cases, respectively. The primary outcome was encountered in 29.0% (95% CI 26.6, 31.5) of participants, while 10.6% (9.0, 12.4) died and 18.0% (16.0, 20.2) were discharged on day 7. In univariate analysis, characteristics prior to admission significantly associated with the primary outcome were sex, BMI and previous treatment with renin-angiotensin-aldosterone system (RAAS) blockers, but not age, type of diabetes, HbA[SUB]1c[/SUB], diabetic complications or glucose-lowering therapies. In multivariable analyses with covariates prior to admission, only BMI remained positively associated with the primary outcome (OR 1.28 [1.10, 1.47]). On admission, dyspnoea (OR 2.10 [1.31, 3.35]), as well as lymphocyte count (OR 0.67 [0.50, 0.88]), C-reactive protein (OR 1.93 [1.43, 2.59]) and AST (OR 2.23 [1.70, 2.93]) levels were independent predictors of the primary outcome. Finally, age (OR 2.48 [1.74, 3.53]), treated obstructive sleep apnoea (OR 2.80 [1.46, 5.38]), and microvascular (OR 2.14 [1.16, 3.94]) and macrovascular complications (OR 2.54 [1.44, 4.50]) were independently associated with the risk of death on day 7.
Conclusions/interpretations: In people with diabetes hospitalised for COVID-19, BMI, but not long-term glucose control, was positively and independently associated with tracheal intubation and/or death within 7 days.
Trial registration: clinicaltrials.gov NCT04324736.

Keywords: BMI; COVID-19; Death; Diabetes; HbA1c; Hypertension; Mechanical ventilation.
 
Back
Top Bottom